Spartalizumab Biosimilar (PDCD1 / PD-1 / CD279 Reference Antibody)
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) .
Product Specifications
Target
Spartalizumab Biosimilar (Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Cancer Biology; Immunology & Inflammation; Cell Biology
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog